(688658)"Youcare Pharmaceutical Group Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688658 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in both revenue and net profit compared to the same period last year, with the company experiencing losses. Additionally, the report highlights an increase in research and development expenditures as part of the company's ongoing projects. The financial statements included in the report have not been audited, and the company assures the accuracy and completeness of the information provided.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Youcare Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Youcare Pharmaceutical
- (688658)"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of the Receipt of Marketing Approval for the New Drug Zihua Wenfei Zhisou Granules
- Announcement on Voluntary Disclosure of the Subsidiary's YKYY036 Injection Obtaining Clinical Trial Approvals from the National Medical Products Administration and the U.S. Food and Drug Administration
- Announcement on Opening a Raised Funds Account and Signing a Supervision Agreement for Deposit of Raised Funds in Special Account
- Announcement on the Use of a Portion of Over-raised Funds for Investment in New Projects
- Announcement on Voluntary Disclosure of the Subsidiary's Receipt of FDA Clinical Trial Approval for YKYY033 Injection
Follow Youcare Pharmaceutical into a list and get an email when it puts out news.
Follow Youcare Pharmaceutical